共 50 条
- [31] Implication of First-Line Antiretroviral Therapy Choice on Second-Line OptionsOPEN FORUM INFECTIOUS DISEASES, 2017, 4 (04):Meloni, Seema T.Onwuamah, Chika K.Agbaji, OcheChaplin, BethOlaleye, David O.Audu, RosemarySamuels, JayEzechi, OliverImade, GodwinMusa, Adesola Z.Odaibo, GeorginaOkpokwu, JonathanRawizza, HollyMu'azu, Muhammad A.Dalhatu, IbrahimAhmed, MukhtarOkonkwo, ProsperRaizes, ElliotUjah, Innocent A. O.Yang, ChunfuIdigbe, Emmanuel O.Kanki, Phyllis J.
- [32] The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIsBLOOD, 2023, 142Giai, ValentinaStagno, FabioRosso, TizianaCastagnetti, FaustoCapodanno, IsabellaBonifacio, MassimilianoTiribelli, MarioGalimberti, SaraBocchia, MonicaGozzini, AntonellaCaocci, GiovanniPatriarca, AndreaLanzarone, GiuseppeGuella, AnnaSora, FedericaLuciano, LuigianaScortechini, Anna Ritadi Renzo, NicolaMusto, PellegrinoPastore, DomenicoMaggi, AlessandroFava, CarmenPavone, VincenzoFozza, ClaudioSpinosa, GiuseppinaCarella, Angelo MicheleTarantini, GiuseppeMartino, BrunoPizzuti, MicheleMannarella, ClaraSaccona, FabioRosti, GianantonioPregno, PatriziaBreccia, MassimoPane, FabrizioCiccone, GiovanninoSpecchia, GiorginaSaglio, Giuseppe
- [33] First-line therapy for CML: decisions, decisionsLANCET HAEMATOLOGY, 2015, 2 (03): : E89 - E90Davies, Jeff
- [35] Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study GroupINTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (01) : 60 - 70Iriyama, NoriyoshiIwanaga, EisakuKimura, YutaWatanabe, NaokiIshikawa, MahoNakayama, HitomiSato, ErikoTabayashi, TakayukiMitsumori, ToruTakaku, TomoikuNakazato, TomonoriTokuhira, MichihideFujita, HiroyukiAndo, MikiHatta, YoshihiroKawaguchi, Tatsuya
- [36] Complexity of chronic-phase CML management after failing a second-generation TKILEUKEMIA & LYMPHOMA, 2020, 61 (04) : 776 - 787El Fakih, RiadChaudhri, NaeemAlfraih, FerasRausch, Caitlin R.Naqvi, KiranJabbour, Elias
- [37] Second-Line Therapy for Patients With Chronic Myeloid Leukemia Resistant to First-Line ImatinibCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (03): : 186 - 196Lau, AnnaSeiter, Karen
- [38] Impact of Second-Generation Tyrosine Kinase Inhibitors As Second Line Treatment for Patients with Chronic Myeloid LeukemiaBLOOD, 2011, 118 (21) : 1615 - 1615Valentin Garcia-Gutierrez, J.Herrera, PilarAbalo, Lorena L.Dolores Rey, MariaCalbacho, MariaRamos, LourdesRamos, PalomaMontalban, CarlosLopez-Jimenez, Javier
- [39] First-Line and second Line Treatment for Patients with Neisseria GonorrhoeaeGYNAKOLOGE, 2019, 52 (01): : 5 - 5不详
- [40] Outcome after Discontinuation of Second Generation Tyrosine Kinase Inhibitors (TKIs) Used As Frontline Therapy for Patients (pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML)BLOOD, 2017, 130Abdelall, WaleedKantarjian, Hagop M.Devendra, K. C.Akosile, MaryBorthakur, GautamVerstovsek, SrdanDaver, NavalPemmaraju, NaveenNaqvi, KiranGarcia-Manero, GuillermoThompson, Philip A.Ferrajoli, AlessandraRavandi, FarhadKonopleva, MarinaDiNardo, Courtney D.Jabbour, Elias J.Cortes, Jorge E.